Breakthrough in Cancer Treatment: Ewingella americana Eradicates Tumors in Mice

Researchers at the Japan Advanced Institute of Science and Technology (JAIST) have identified a bacterium, Ewingella americana, isolated from the gut microbiota of Japanese tree frogs (Dryophytes japonicus), that demonstrates remarkable potential in cancer treatment. In laboratory tests, this bacterium completely eradicated tumors in mice with a single intravenous dose, achieving a 100% complete response (CR) rate in a colorectal cancer model. This outcome surpasses the effectiveness of established cancer therapies, including immune checkpoint inhibitors and chemotherapy agents.

SciTechDaily

E. americana employs two primary mechanisms to combat tumors. First, it exhibits a direct cytotoxic effect by preferentially accumulating in the low-oxygen environment of tumors, where it multiplies significantly and directly damages cancer cells. Second, it activates the immune system by attracting T cells, B cells, and neutrophils to the tumor site. These immune cells release pro-inflammatory cytokines, such as TNF-? and IFN-?, which enhance immune activity and promote apoptosis in cancer cells.

SciTechDaily

The bacterium's ability to selectively target tumor tissue is attributed to several biological factors. Tumor environments often feature low oxygen levels, local immune suppression due to proteins like CD47 produced by cancer cells, and leaky blood vessels that facilitate bacterial entry. Additionally, unique metabolic byproducts produced by cancer cells support the growth of E. americana within tumors while preventing its proliferation in healthy tissues.

SciTechDaily

Comprehensive safety assessments indicate that E. americana has a favorable safety profile, with rapid clearance from the bloodstream and no detectable presence in normal organs. Mild inflammatory responses observed were short-lived, returning to baseline within 72 hours, with no long-term toxicity noted during a 60-day observation period.

SciTechDaily

Future research will focus on expanding the application of E. americana to other cancer types, such as breast, pancreatic, and melanoma cancers. Additionally, efforts will be made to improve delivery methods and explore combination therapies with existing immunotherapies and chemotherapies. This research underscores the potential of biodiversity in developing new medical technologies and treatment options for patients with resistant cancers.

SciTechDaily

The study, published in the journal Gut Microbes, highlights a novel approach to cancer treatment that diverges from traditional methods. Prof. Eijiro Miyako emphasized the significance of isolating individual bacterial strains for targeted therapy, stating, "This research provides proof of concept for a new cancer treatment strategy that uses naturally occurring bacteria."

SciTechDaily

While the findings are promising, some experts caution against overestimating the immediate applicability of this treatment in humans. Concerns regarding the long-term effects and the need for extensive clinical trials before human application have been raised.

SciTechDaily

• “2 hours, completely undetectable at 24 hours) No bacterial presence detected in normal organs, including liver, spleen, lung, kidney, and heart Only short-lived mild inflammatory responses, which return to normal within 72 hours No signs of long-term toxicity during a 60-day extended observation period Future Directions This research provides proof of concept for a new cancer treatment strategy that uses naturally occurring bacteria.” — Prof. Eijiro Miyako, Japan Advanced Institute of Science and Technology

SciTechDaily

This groundbreaking research opens new avenues in cancer therapy, potentially transforming treatment paradigms and improving outcomes for patients facing challenging malignancies.

SciTechDaily